Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Earth Science Tech, Inc. (ETST)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.01600.0000 (0.00%)
At close: 10:37AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0160
Open0.0205
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0160 - 0.0205
52 Week Range0.0100 - 0.0694
Volume6,050
Avg. Volume49,612
Market Cap876,529
Beta (5Y Monthly)0.89
PE Ratio (TTM)0.29
EPS (TTM)0.0560
Earnings DateJul 15, 2020 - Jul 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ETST

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • EARTH SCIENCE TECH INC
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
  • GlobeNewswire

    Earth Science Tech, Inc. (ETST) Executes Phase I Acquisition of RxCompoundStore.com, LLC. and Peaks Curative, LLC.

    DORAL, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and medical devices, today announces execution of Phase I acquisition of RxCompoundstore.com, LLC. (“RxCS”) and Peaks Curative, LLC. (“PC”) as part of the Company’s new direction and announced dual phase transaction. As of November 3, 2021 RxCS and PC have become a wholly owned subsidiaries under ETST. The t

  • GlobeNewswire

    Earth Science Tech, Inc. (ETST) Announces Acquisition Structure with RxCompoundstore.com, LLC., Peaks Curative, LLC., and JCR Medical Equipment, Inc.

    DORAL, FL, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and medical devices, today announces its planned acquisition structure with RxCompoundstore.com, LLC. (“RxCS”), Peaks Curative, LLC. (“PC”), and JCR Medical Equipment (“JCR”), Inc. as part of the Company’s new direction announced earlier this week. The Company has discussed and plans to proceed with the acqu

  • GlobeNewswire

    Earth Science Tech, Inc. (ETST) Becomes Current with the SEC and Shares Updates to the Market

    DORAL, Florida, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company nutraceutical and pharmaceutical fields, and medical devices, announces they have become current with the SEC, and shares updates to the market. Company regains its current status with the SEC after filing its, both, delinquent period ending March 31, 2021 year end and period ending June 30, 2021 quarter. This was achieved through the supervision of the

Advertisement
Advertisement